Loews Free cash flow decreased by 131.0% to -$132.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 120.7%, from $638.00M to -$132.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 6.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $313.00M | $989.00M | $792.00M | $302.00M | $832.00M | $1.12B | $399.00M | $560.00M | $1.29B | $1.11B | $254.00M | $39.00M | $793.00M | $794.00M | $767.00M | $638.00M | $872.00M | $764.00M | $426.00M | -$132.00M |
| QoQ Change | — | +216.0% | -19.9% | -61.9% | +175.5% | +34.7% | -64.4% | +40.4% | +131.1% | -14.0% | -77.2% | -84.6% | >999% | +0.1% | -3.4% | -16.8% | +36.7% | -12.4% | -44.2% | -131.0% |
| YoY Change | — | — | — | — | +165.8% | +13.3% | -49.6% | +85.4% | +55.5% | -0.7% | -36.3% | -93.0% | -38.7% | -28.7% | +202.0% | >999% | +10.0% | -3.8% | -44.5% | -120.7% |